This site has been blessed with recognition on several occasions. Thanks to all who feature this site on theirs - sharing of information is the primary goal.
Excite Recommended Web Site for Lymphoma
Yahoo Cool Site for Lymphoma
CNN special cancer issue - focus on Lymphoma
Open Directory Cool Site for NHL 3/2001
The site was chosen a MedExplorer Top Rated site in August 1999. Thank you!
Sincere thanks to About.Com
Healthway Best of the Web
This was a Health A to Z 5 star site
We were chosen a Healthnet Canada 5 star site in June 1999
This site was the LA Times Pick of the Week for February 8, 1999
Also as seen in the Boston Globe Magazine April 25, 1999
and the New York Times July 9, 1998 - Thank You!
Lately the site has been listed in a number of books - I will try to list them as I run across the references:
• Living with Lymphoma by Elizabeth Adler, 2005,
page 13
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...